Cue Biopharma (CUE) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed PepGen (PEPG) over the past year, losing 0.2% versus a loss of 51.1%. PepGen is the larger company by market cap ($166.0 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | PEPG |
|---|---|---|
| Share price | $22.51 | $2.40 |
| Market cap | $163.52M | $166.01M |
| 1-day change | -2.72% | +3.90% |
| YTD return | +146.01% | -63.13% |
| 1-year return | -0.22% | -51.12% |
| 5-year return | -94.04% | — |
| EPS (TTM) | $-28.75 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $7.80 |
| 52-week low | $4.98 | $1.31 |
| Distance from 52-week high | -50.53% | -69.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +290.94% | +324.58% |
| Average volume | 269.82K | 976.87K |
| Shares outstanding | 7.26M | 69.17M |
| Employees | 29 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed PEPG by 50.9 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CUE vs PEPG FAQ
Which is bigger, Cue Biopharma or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $166.01M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or PEPG?
CUE returned -0.22% over the past 12 months, compared with -51.12% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.